Klaus Bosslet

Elucidation of the mechanism enabling tumor selective prodrug monotherapy.

Klaus Bosslet, Rainer H. Straub, Matthias Blumrich et al. · PubMed · 1998 · 226 citations

Tumor Biology, Drug Targeting, Oncology +14

RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis

Peter Brünker, Katharina Wartha, Thomas Friess et al. · Molecular Cancer Therapeutics · 2016 · 131 citations · Full text

Tumor-selective prodrug activation by fusion protein-mediated catalysis.

Klaus Bosslet, Jörg Czech, Dieter Hoffmann · PubMed · 1994 · 127 citations

Drug Targeting, Oncology, Tumor-selective Prodrug Activation +13

Dual IGF-I/II–Neutralizing Antibody MEDI-573 Potently Inhibits IGF Signaling and Tumor Growth

Jin Gao, Jon Chesebrough, Susan A. Cartlidge et al. · Cancer Research · 2011 · 119 citations

Insulin-like Growth Factors, Tumor Growth, Medicine +14

Tumor metastases and cell‐mediated immunity in a model system in DBA/2 mice.: Iv. Antigenic differences between a metastasizing variant and the parental tumor line revealed by cytotoxic T lymphocytes

Volker Schirrmacher, Klaus Bosslet, Geraldine D. Shantz et al. · International Journal of Cancer · 1979 · 114 citations